Hansa Biopharma Q2 2023 Investor Presentation

Hansa Biopharma's Q2 2023 investor roadshow presentation covers business updates, clinical development programs, and commercialization strategy for imlifidase in kidney transplantation. The deck details the company's enzyme technology platform, ongoing studies, gene therapy initiatives, and capital markets outlook.